Bionomics’ BNC210 anti-anxiety drug enters phase I
Friday, 21 December, 2012
Bionomics’ (ASX:BNO) US partner, Ironwood Pharmaceuticals, has moved forward with development of anti-anxiety drug IW-2143, also known as BNC210, by initiating a phase I trial.
The company filed an Investigational New Drug application with the Food and Drug Administration in November.
The phase I trial will assess safety and pharmacokinetics of BNC210 in healthy volunteers using single and multiple doses.
“This is the first US clinical trial of IW-2143 and this news is welcomed by Bionomics as a strong signal of the progress being made by Ironwood in moving ahead with the study of IW-2143,” said Bionomics CEO and MD, Dr Deborah Rathjen.
Bionomics is expecting a US$2m milestone payment from Ironwood as the trial progresses.
Bionomics’ (ASX:BNO) lost half a cent in morning trading, sitting at 35c as of around 11am Friday.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
